Member Info for Bridges

correct TO news or licencing deal will instantly re rate sp and if you have forward sold you will be facing massive market call. Usually I dont wish anything bad on individuals but in the circumstances where it is underhand then I hope the turd/turds who have paid all these trolls, you know who you are, get caught in a forward position when the TO news drops. It would be poets justice. What would be more amusing if the share was temporally suspended and they still had fwd sells open, just saying

Ahfam lol btw b&q are doing 2 vomit buckets for the price of one.

Support advice corner lol

I agree we are infested with c-wombles talking toilet

Oh no it’s not.

Sp should be marked up by at least 5p

COVID-19: UK to look 'very carefully' at vaccine dosing after concerns raised over level of protection
http://news.sky.com/story/covid-19-uk-to-look-very-carefully-at-vaccine-dosing-after-concerns-raised-over-level-of-protection-12193205

Will we see the first human trails of 1801 in French hospitals. I am sure one of those links boil posted gave an insight to this

Condolences Mufta

Here they come 2m ish so far. Maybe more up their sleeves

Seems there may be more volume on the horizon, with the addition of MREX last week; tail tail signs of imminent re-rate on the near horizon.

Hey workingp no I wasn’t referring to you. The likes of realroger.
This is my opinion due to the fact it is of national importance. Plus we are no longer under the radar. Plus preclinical work needed for the first Clinical Trial Application will be completed during Q1. Human trails thereafter. Hence my statement that it will be funded either way by TO candidates of which we are aware that BOD are is negotiations or Boris.

TYK2/JAK1 programme matter of national importance paid for by potential TO candidate or Boris will pay for P1 and P2. 1801 will be entering into human studies very soon ; )

Can someone shut it and dont respond to them. FYI Not enough shares mm are short.

Worth remembering where the generation of shareholder value is coming from.

"Our clear priority focus remains on advancing our proprietary TYK2/JAK1 programmes and, in the near-term, on completing the preclinical work needed for the first Clinical Trial Application during the first quarter of the year. Achieving this important milestone will be a key step in generating shareholder value from our TYK2/JAK1 pipeline." 50% completed now!

SAR IP also supported recently by the Nature publication that TYK2 has been Identified as a Key Genetic Mechanism of Critical Illness in Covid-19 plus potential target for Therapy.

SAR also investigating 1801 as protection/treatment against bacterial pneumonia following SARS-CoV-2 infection.
TYK2/JAK1 programme matter of national importance paid for by potential TO candidate or Boris will pay for P1 and P2. 1801 will be entering into human studies very soon ; ) Tick

A lot of multi billion dollar deals going through for immunotherapy ie: latest of many Sanofi buys UK immunotherapy firm Kymab for $1.45 billion. Tick

SAR Multi Billion Jigsaw completed. Tick

Forgot to mention we are over 50% of the way through this now:

"Our clear priority focus remains on advancing our proprietary TYK2/JAK1 programmes and, in the near-term, on completing the preclinical work needed for the first Clinical Trial Application during the first quarter of the year. Achieving this important milestone will be a key step in generating shareholder value from our TYK2/JAK1 pipeline."

Worth remembering where the generation of shareholder value is coming from.

"Our clear priority focus remains on advancing our proprietary TYK2/JAK1 programmes and, in the near-term, on completing the preclinical work needed for the first Clinical Trial Application during the first quarter of the year. Achieving this important milestone will be a key step in generating shareholder value from our TYK2/JAK1 pipeline."

SAR IP also supported recently by the Nature publication that TYK2 has been Identified as a Key Genetic Mechanism of Critical Illness in Covid-19 plus potential target for Therapy.

SAR also investigating 1801 as protection/treatment against bacterial pneumonia following SARS-CoV-2 infection.
TYK2/JAK1 programme matter of national importance paid for by potential TO candidate or Boris will pay for P1 and P2. 1801 will be entering into human studies very soon ; ) Tick

A lot of multi billion dollar deals going through for immunotherapy ie: latest of many Sanofi buys UK immunotherapy firm Kymab for $1.45 billion. Tick

SAR Multi Billion Jigsaw completed. Tick

May explain the MREX registration

Glen well said! Maybe Damian is a little uncomfortable with the new MM. just saying

Marex is the new market maker on the block and is now interestingly registered for SAR. IMO this is very positive that will add to the mix of the existing MMs. Marex is one of the worlds largest, they are global with access to US. Maybe linked to hedge fund, or hedge funds or acquisition .... This is what I have been waiting for and is a clear signal to get your vomit buckets ready.

Never be I should have done/I should have been person. It will not do you any favours ;)